About Innara Health
Innara Health develops feeding technologies to measure and treat infants, children, and adults that struggle with suck, swallow, and breathe coordination. The company offers a neonatal technology that assesses and develops non-nutritive suck skills for newborns and infants born prematurely. Innara Health was formerly known as KC BioMediX. The company was founded in 2006 and is based in Olathe, Kansas.
Expert Collections containing Innara Health
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Innara Health is included in 1 Expert Collection, including Baby and Kids Tech.
Baby and Kids Tech
Companies developing tech-enabled products and services that primarily serve babies, children up to approximately 12 years old, and their parents.
Innara Health Patents
Innara Health has filed 10 patents.
Software testing, Motor control, Dosage forms, Intensive care medicine, Drug delivery devices
Software testing, Motor control, Dosage forms, Intensive care medicine, Drug delivery devices
Latest Innara Health News
Sep 5, 2023
Biohealth Innovation Tuesday, September 5, 2023 In a significant stride towards advancing improvements in neonatal care, BioHealth Innovation, Inc. (BHI) portfolio company and client, Innara Health, has become an integral part of Cardinal Health – a leading distributor of pharmaceuticals, a global manufacturer and distributor of medical and laboratory products, and a provider of performance and data solutions for healthcare facilities, This strategic integration underscores Innara Health’s dedication to improving neonatal feeding outcomes, a commitment that has been nurtured through a collaborative journey involving prominent industry figures and organizations. Background and Collaborative Journey The evolution of Innara Health’s transformative medical device has been fueled by a collaborative effort involving key players in the healthcare and investment sectors. The journey, which began in with FDA clearance in 2008, pivoted in 2019 when Keith Molzer, Founder and Managing Partner of Flyover Capital and Innara Health Board Chair, played a pivotal role in recruiting Chris Mathia already with Innara Health as Vice President of Sales in 2017, to ascend to the role of CEO. A crucial turning point for Innara Health came through Keith Molzer’s enduring relationship with BioHealth Innovation’s President & CEO, Rich Bendis, leading Innara Health to engage BHI’s services as a client and eventual portfolio company. BHI facilitated Innara’s pursuit of non-dilutive funding through application for SBIR grants, identified key opinion leaders (KOLs), partners, and connected them with the investment community. One of these connections led Innara to Ethel Rubin, Ph.D., an Entrepreneur-in-Residence (EIR) with BHI, who joined Innara’s Board of Directors. Ethel and Rich’s involvement led to a cascade of connections, including a meeting with Kolaleh Eskandanian, Ph.D., MBA, PMP, and Chief Innovations Officer from Children’s National Hospital, leading to Innara Health becoming a portfolio company of the National Capital Consortium for Pediatric Device Innovation (NCC-PDI). This connection provided invaluable guidance, placed Innara in front of influential clinicians and opinion leaders, and ultimately led to their participation in the MedTech Innovator 2021 Pediatric cohort – a six-month accelerator program. During this period, Innara Health secured $50,000 in non-dilutive funding from the FDA through the Children’s National and MedTech Innovator’s Accelerator and Venture Competition, “Make Your Medical Device Pitch for Kids.” The Path to Cardinal Health As Innara Health’s trajectory progressed, the company embarked on a redesign of its innovative NTrainer™ System medical device. Through her guidance and position on Innara’s Board of Directors, Ethel Rubin connected Innara with Strategic Lifesciences investment banking firm Outcome Capitol. Outcome Capitol played a pivotal role in introducing Innara Health to numerous strategic healthcare companies, resulting in Cardinal Health’s interest in Innara. This union marks a significant milestone as Innara Health’s pioneering technology becomes integral to Cardinal Health’s mission to enhance neonatal care. With this strategic integration, Innara Health’s innovative approach to improving neonatal feeding outcomes is poised to have a broader impact under the auspices of Cardinal Health. This collaboration aligns with Cardinal Health’s reputation as a trusted industry leader, combining their distribution prowess with Innara Health’s cutting-edge neonatal care solutions. “The trajectory of our organization changed immensely once we engaged with BHI,” shared Chris Mathia, CEO of Innara Health. “The access to BHI staff with deep domain expertise, their guidance, the introductions to KOL’s, and the sheer number of opportunities we were presented with was both staggering and critical in our journey. Dr. Rubin’s guidance as a board member was particularly invaluable. It was a luxury, especially for a small med-tech company based in Kansas, to have daily access to someone with her experience and network. Her impact, as was BHI’s, was instrumental to our success.” “The result of Innara Health and The NTrainer becoming an innovation addition within Cardinal Health’s nutritional delivery portfolio of solutions demonstrates the depth of BHI, its resources, and networks that help our clients,” noted Rich Bendis, President & CEO of BioHealth Innovation, Inc. “We take pride in fostering collaborations and connections that propel innovative healthcare solutions forward. This achievement demonstrates how BHI’s dedicated support empowers our clients to develop groundbreaking technologies and successfully navigate the complex landscape of healthcare industry partnerships. We congratulate Innara Health and celebrate this integration as a testament to the strength of the BioHealth ecosystem.” For the original press release regarding Cardinal Health’s launch of the NTrainer™ System 2.0 and Innara Health’s integration, click here .
Innara Health Frequently Asked Questions (FAQ)
When was Innara Health founded?
Innara Health was founded in 2006.
Where is Innara Health's headquarters?
Innara Health's headquarters is located at 10900 S Clay Blair Boulevard, Olathe.
What is Innara Health's latest funding round?
Innara Health's latest funding round is Corporate Minority.
How much did Innara Health raise?
Innara Health raised a total of $6.37M.
Who are the investors of Innara Health?
Investors of Innara Health include Cardinal Health, National Capital Consortium for Pediatric Device Innovation, MedTech Innovator, KCRise Fund, Kansas Technology Enterprise Corporation and 6 more.
Who are Innara Health's competitors?
Competitors of Innara Health include BrainScope, Ativa Medical, Infrascan, Senseonics, Third Eye Diagnostics and 13 more.
Compare Innara Health to Competitors
Third Eye Diagnostics is developing the Cerepress, a first-of-its-kind non-invasive intracranial pressure monitor that gathers information from the patient's eye. The technology is based on one issued patent, one pending patent, and two applications in progress on methods and apparatus that correlate ICP with measurements taken from the blood vessels within the eye. The Cerepress measures blood pressure in the eye's central retinal vein (CRV) which highly correlates to intracranial pressure.
NeuroDx addresses important unmet needs in the neurosurgical market. Their lead product, ShuntCheck, is an aid to the detection offlow in implanted cerebrospinal fluid (CSF) shunts.
MEC Dynamics is a medical devices company developing and manufacturing point-of-care diagnostic products, using its proprietary technology. The company's devices have been designed for use in the both physician's office as well as the patient's home. They enable the 'real time' measurement of key blood analytes for early detection and more effective management of a variety of diseases including diabetes, cardiovascular diseases and cancer. Chronic and life-threatening diseases occurring in both industrial and developing countries could be better treated through early detection and proper monitoring. MEC aims to be a global developer and manufacturer of point-of-care diagnostic products using its technology platform. MEC's lead product, AvieA1c, is FDA 510K approved and NGSP certified.
Pelikan Technologies is dedicated to the development of hand-held diagnostic and monitoring devices capable of improving the screening and management of a variety of medical conditions. In addition to diabetes, the company's versatile technology platform has applications across a range of other medical conditions that involve blood screening and monitoring. Point-of-care testing and diagnostic panel test systems also represent markets that can benefit from Pelikan's technology. The Pelikan Sun can improve the quality of life for people with diabetes by combining several of the company's technologies into the most convenient and effective blood glucose self-monitoring device available. Pelikan's line of diabetes management tools will address the pain and inconvenience that has stymied the industry's manufacturers, and plagued people with diabetes, contributing to poor blood glucose monitoring compliance. By targeting these barr
EyeSense develops an ophthalmic diagnostics system which can measure glucose levels without sampling blood. It is based on measuring the glucose in the interstitial fluid below the conjunctiva of the eye using a hand-held optical read-out device.
InfraScan is developing handheld screening devices for patients in two areas: stroke and traumatic brain injury. The company's flagship product, the Infrascanner handheld imaging device, uses near infrared (NIR) light to screen for intracranial bleeding in patients with head trauma. The results of screening can be used to expedite high-risk patients for CT scanning or surgical intervention.